..... even with another ADC failure and all the ADC deals being done, Starpharma still don't seem to be able to sign an ADC license deal at this stage ?
I wonder if Gilead's failure will see them branch out ? I wonder if Gilead ever returned JF's call back in September 2020 in relation to the DEP® Remdesivir results she was touting to the market ?
https://www.healio.com/news/hematol...etastatic-lung-cancer-misses-primary-endpoint
Phase 3 study of Trodelvy for advanced lung cancer misses primary endpoint
Sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences) is a Trop-2-directed antibody-drug conjugate. The agent is approved for treatment of certain patients with breast cancer or urothelial cancer.
Another ADC Buyout - Just not SPL, page-15
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $41.31M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.9¢ | $14.97K | 151.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 372123 | 9.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 5042 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| SPL (ASX) Chart |